tetano
Editor, Senior Moderator
Vaccine
. 2021 Jul 16;S0264-410X(21)00911-7.
doi: 10.1016/j.vaccine.2021.07.034. Online ahead of print.
An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity
Anne-Catherine Fluckiger[SUP] 1 [/SUP], Barthelemy Ontsouka[SUP] 2 [/SUP], Jasminka Bozic[SUP] 2 [/SUP], Abebaw Diress[SUP] 2 [/SUP], Tanvir Ahmed[SUP] 2 [/SUP], Tamara Berthoud[SUP] 2 [/SUP], Anh Tran[SUP] 3 [/SUP], Diane Duque[SUP] 3 [/SUP], Mingmin Liao[SUP] 4 [/SUP], Michael McCluskie[SUP] 3 [/SUP], Francisco Diaz-Mitoma[SUP] 5 [/SUP], David E Anderson[SUP] 5 [/SUP], Catalina Soare[SUP] 2 [/SUP]
Affiliations
Abstract
We evaluated enveloped virus-like particles (eVLPs) expressing various forms of the Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein and several adjuvants in an effort to identify a highly potent Coronavirus disease 2019 (COVID-19) vaccine candidate. eVLPs expressing a modified prefusion form of SARS-CoV-2 spike protein were selected as they induced high antibody binding titers and neutralizing activity after a single injection in mice. Formulation of SARS-CoV-2 S eVLPs with aluminum phosphate resulted in balanced induction of IgG2 and IgG1 isotypes and antibody binding and neutralization titers were undiminished for more than 3 months after a single immunization. A single dose of this candidate, named VBI-2902a, protected Syrian golden hamsters from challenge with SARS-CoV-2 and supports the on-going clinical evaluation of VBI-2902a as a highly potent vaccine against COVID-19.
Keywords: Immunogenicity; Neutralizing antibodies; SARS-COV-2; Vaccine; Virus-like-particles.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Anne-Catherine Fluckiger reports a relationship with VBI Vaccines Inc that includes: consulting or advisory. Barthelemy Ontsouka reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks. Jasminka Bozic reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks. Abebaw Diress reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks. Tanvir Ahmed reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks. Tamara Berthoud reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks. Anh Tran reports a relationship with National Research Council Canada that includes: employment. Diane Duque reports a relationship with National Research Council Canada that includes: employment. Liao Mingmin reports a relationship with Vaccine and Infectious Disease Organization International Vaccine Centre that includes: employment. Michael McCluskie reports a relationship with National Research Council Canada that includes: employment. Francisco Diaz-Mitoma reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks. David E. Anderson reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks. Catalina Soare reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks].
. 2021 Jul 16;S0264-410X(21)00911-7.
doi: 10.1016/j.vaccine.2021.07.034. Online ahead of print.
An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity
Anne-Catherine Fluckiger[SUP] 1 [/SUP], Barthelemy Ontsouka[SUP] 2 [/SUP], Jasminka Bozic[SUP] 2 [/SUP], Abebaw Diress[SUP] 2 [/SUP], Tanvir Ahmed[SUP] 2 [/SUP], Tamara Berthoud[SUP] 2 [/SUP], Anh Tran[SUP] 3 [/SUP], Diane Duque[SUP] 3 [/SUP], Mingmin Liao[SUP] 4 [/SUP], Michael McCluskie[SUP] 3 [/SUP], Francisco Diaz-Mitoma[SUP] 5 [/SUP], David E Anderson[SUP] 5 [/SUP], Catalina Soare[SUP] 2 [/SUP]
Affiliations
- PMID: 34304928
- DOI: 10.1016/j.vaccine.2021.07.034
Abstract
We evaluated enveloped virus-like particles (eVLPs) expressing various forms of the Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein and several adjuvants in an effort to identify a highly potent Coronavirus disease 2019 (COVID-19) vaccine candidate. eVLPs expressing a modified prefusion form of SARS-CoV-2 spike protein were selected as they induced high antibody binding titers and neutralizing activity after a single injection in mice. Formulation of SARS-CoV-2 S eVLPs with aluminum phosphate resulted in balanced induction of IgG2 and IgG1 isotypes and antibody binding and neutralization titers were undiminished for more than 3 months after a single immunization. A single dose of this candidate, named VBI-2902a, protected Syrian golden hamsters from challenge with SARS-CoV-2 and supports the on-going clinical evaluation of VBI-2902a as a highly potent vaccine against COVID-19.
Keywords: Immunogenicity; Neutralizing antibodies; SARS-COV-2; Vaccine; Virus-like-particles.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Anne-Catherine Fluckiger reports a relationship with VBI Vaccines Inc that includes: consulting or advisory. Barthelemy Ontsouka reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks. Jasminka Bozic reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks. Abebaw Diress reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks. Tanvir Ahmed reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks. Tamara Berthoud reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks. Anh Tran reports a relationship with National Research Council Canada that includes: employment. Diane Duque reports a relationship with National Research Council Canada that includes: employment. Liao Mingmin reports a relationship with Vaccine and Infectious Disease Organization International Vaccine Centre that includes: employment. Michael McCluskie reports a relationship with National Research Council Canada that includes: employment. Francisco Diaz-Mitoma reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks. David E. Anderson reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks. Catalina Soare reports a relationship with VBI Vaccines Inc that includes: employment and equity or stocks].